REFERENCES | |
__________________________ | |
1 |
Leukemia & Lymphoma Society of Canada. Facts and Statistics. http://www.llscanada.org/disease-information/facts-and-statistics. Last accessed on February 27, 2018. |
2 |
RITUXAN SC Product Monograph. March 21, 2018. |
3 |
Assouline, Sarit et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER). Lancet Haematology.2016. |
4 |
Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G. 2014. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. |
5 |
Leukemia & Lymphoma Society of Canada. Chronic Lymphocytic Leukemia.http://www.llscanada.org/leukemia/chronic-lymphocytic-leukemia. Last accessed February 26, 2018. |
6 |
Leukemia & Lymphoma Society of Canada. Chronic Lymphocytic Leukemia. http://www.llscanada.org/leukemia/chronic-lymphocytic-leukemia. Last accessed February 26, 2018. |
7 |
Lymphoma Canada. About CLL & SLL. https://www.lymphoma.ca/lymphoma/cll-sll/about-cll-sll. Last accessed on February 26, 2018. |
8 |
RITUXAN SC Product Monograph. March 21, 2018. |
9 |
RITUXAN SC Product Monograph. March 21, 2018. |
10 |
RITUXAN SC Product Monograph. March 21, 2018. |
11 |
RITUXAN SC Product Monograph. March 21, 2018. |
12 |
RITUXAN SC Product Monograph. March 21, 2018. |
13 |
RITUXAN SC Product Monograph. March 21, 2018. |
14 |
RITUXAN SC Product Monograph. March 21, 2018. |